Balt Group
Manufacturing · France · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
10 Rue De La Croix Vigneron, Montmorency...Website
www.baltgroup.comRevenue
$213.1 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
2
1
1
1
1
About Balt Group
For more than 45 years, Balt has been leading the way – collaborating with physicians and institutions to develop elegant neurovascular solutions. As the premier global neurovascular platform, always seeking to expand beyond boundaries, we are now bringing our innovation to the peripheral vascular space.Explore more
Balt Group Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Balt Group your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Balt Group launches new products
Check if Balt Group has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Balt Group has new funding data
Balt Group, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Balt Group recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Balt Group
Check out if Balt Group is spiking on competitors!
Click to see if Balt Group had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Balt Group as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Balt Group is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Balt Group is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Balt Group.
Balt Group financials insights
Gather financial insights about Balt Group, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Other Financing Round
$370M
Balt Group Tech Stack
A closer look at the technologies used by Balt Group
Most Recent Scoops
Open Position
Hiring Plans
Balt Group has more open roles in Operations than it has had at any time in the past 12 months.
Hiring Plans
Open Position
Open Position
Funding
Funding
Balt Group News & Media
Balt’s Squid™ Liquid Embolic Receives FDA Approval for Adjunctive Treatment for Patients with Chronic Subdural Hematomas
BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Balt, Inc., a global technology leader in neurovascular devices, today announced the Premarket Approval (PMA) of the Squid™ liquid embolic agent. Squid is approved for the embolization of the middle meningeal artery (MMA) as an adjunct to usual care treatment in patients with large symptomatic chronic subdural hematoma(s) (cSDH).Balt USA Responds to Patent Infringement Lawsuit Filed by Route 92 Medical
IRVINE, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Balt USA, LLC (“Balt”), a global leader in neurovascular medical devices, today announced it intends to vigorously defend against the allegations of patent infringement filed by Route 92 Medical, Inc. against the company.Balt secures €355 million to refinance its debt and accelerate its growth
PARIS and MONTMORENCY, France, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Balt, a global medical device leader in interventional neuroradiology, announces that it has secured €355 million in financing from a group of leading institutional investors and banks to refinance existing debt, accelerate product innovation, expand production capacity, and enhance development of key growth markets.Balt Announces Publication in New England Journal of Medicine of The Squid Trial for the Embolization of the Middle Meningeal Artery (STEM) for the Treatment of chronic Sub-Dural Hematoma
BOSTON, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Balt, Inc., a global technology leader in neurovascular devices, today announced the publication of The Squid Trial for the Embolization of the Middle meningeal artery (STEM) for the treatment of chronic Sub-Dural Hematoma in the New England Journal of Medicine. The study shows that among patients with symptomatic chronic subdural hematoma (cSDH), adjunctive middle meningeal artery (MMA) embolization resulted in a lower risk of treatment failure than sta
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Balt Group
Sign Up For FreeTo access detailed company insights
For more than 45 years, Balt has been leading the way – collaborating with physicians and institutions to develop elegant neurovascular solutions. As the premier global neurovascular platform, always seeking to expand beyond boundaries, we are now bringing our innovation to the peripheral vascular space.... Read More
